ARQT vs. INVA, OCUL, KNSA, PHAT, SUPN, ALKS, PRGO, CRNX, AXSM, and MRUS
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Innoviva (INVA), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), and Merus (MRUS). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 5 mentions for Innoviva. Arcutis Biotherapeutics' average media sentiment score of 1.75 beat Innoviva's score of 0.98 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
99.1% of Innoviva shares are held by institutional investors. 1.4% of Innoviva shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Innoviva received 241 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 62.07% of users gave Arcutis Biotherapeutics an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of -204.35%. Arcutis Biotherapeutics' return on equity of 28.94% beat Innoviva's return on equity.
Arcutis Biotherapeutics has a consensus price target of $25.38, suggesting a potential upside of 193.01%. Given Innoviva's higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Innoviva.
Summary
Innoviva beats Arcutis Biotherapeutics on 10 of the 17 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
